Menu

The launch of dienogest tablets provides a new choice for endometriosis patients

Author: Medicalhalo
Release time: 2025-10-19 11:44:20

It is a new type of selective progesterone receptor agonist that can inhibit ovarian function and endometrial cell proliferation, thereby reducing the pain associated with EMs and shrinking and shrinking the lesions. Chinese regulatory authorities have approved dienogest tablets for the treatment of endometriosis (EMs). The launch of dienogest tablets provides a new option for patients with endometriosis.

Endometriosis is a chronic disease that requires long-term management and has a high recurrence rate after surgery. Dienogest tablets (Weisaning) are effective in treating endometriosis pain, can be taken for a long time, are safe and have good compliance. Dienogest tablets (Weisanin) are 17-34 times more effective at converting endometrium than other synthetic progestins. Compared with traditional high-efficiency progestins, dienogest tablets (Weisaning) can efficiently convert ectopic endometrium at 2 mg/day, while many other progestogen drugs must be administered at high doses to inhibit ectopic endometrium and be effective in treating endometriosis-related symptoms.

Dienogest tablets (Weisaning) treat endometriosis through multiple central and peripheral mechanisms. It can moderately inhibit the H-P-O axis, control the patient's estrogen level within a reasonable "therapeutic window", and inhibit endometriosis lesions without increasing low estrogen-like side effects such as hot flashes and bone loss. It has anti-inflammatory, anti-intimal hyperplasia, and anti-angiogenic effects on peripheral lesions, can effectively shrink endometriosis lesions, and significantly relieve endometriosis-related pain.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles:

[ 免责声明 ]  本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。